Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects

Documents similaires

• Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
  par: Irina Baltcheva, et autres
  Publié: (2026)
• Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
  par: C. Hu, et autres
  Publié: (2025)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
  par: Yuhao Wang, et autres
  Publié: (2025)
• Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment
  par: Shibeilei Lin, et autres
  Publié: (2025)
• Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
  Publié: (2024)